---
document_datetime: 2025-08-13 15:31:40
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/stribild-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: stribild-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1933455
conversion_datetime: 2025-12-30 08:42:15.994223
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Stribild

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                     |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 13/08/2025                          | N/A                                         |                                  | To update the RMP by removing the 'Specific |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000284398   | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To update the RMP by removing the 'Specific Adverse Reaction Follow-up Questionaries' related to renal events including tubulopathy and bone events due to proximal renal tubulopathy/loss of bone mineral density (BMD). In addition, the MAH took the opportunity to update Part II (Module SV) with post-authorization exposure data.   | Adverse Reaction Follow-up Questionaries' related to renal events including tubulopathy and bone events due to proximal renal tubulopathy/loss of bone mineral density (BMD).   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|